September 4, 2019

Notice regarding the launch of Collategene® intramuscularinjection 4 mg, an HGF gene therapy productMitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka City; President &Representative Director: Masayuki Mitsuka) and AnGes, Inc. (Head Office: Ibaraki City, Osaka;
President & Representative Director: Ei Yamada) announced today that an NHI drug price listinghas been obtained for Collategene® intramuscular injection 4 mg (Active ingredient: beperminogene
perplasmid), an HGF gene therapy product for critical limb ischemia in Japan. Collategene® will belaunched on Tuesday, September 10, 2019 in Japan.
Collategene® has been a key project for AnGes, which has worked on Collategene® since itsestablishment. On March 26, 2019, AnGes received conditional, time-limited approval for
Collategene® for the improvement of ulcers in patients suffering from Peripheral artery disease.
Collategene® is the first gene therapy product to be approved in Japan. Collategene® is a DNA
plasmid that expresses hepatocyte growth factor (HGF). It is introduced into the lower limb muscle
cells, which are the target cells, transcribed and translated in the muscle cells, and then HGF isproduced and secreted. Through angiogenesis effect of HGF, the number of blood vessels and thelocal blood flow are increased at the site of the ischemia, thereby improving ulcers.
In June 2015, Mitsubishi Tanabe Pharma and AnGes concluded an exclusive sales rights agreement
for sales of HGF gene-therapy products targeting peripheral arterial diseases in Japan. Mitsubishi
Tanabe Pharma will be in charge of sales and marketing of Collategene®. The approval ofCollategene® has conditions and a time limit, and acquisition of official marketing approval will
require the implementation of a post-approval evaluation within the time limit of five years.
Mitsubishi Tanabe Pharma has been commissioned by AnGes to conduct a confirmatory study as thepost-approval evaluation.
Moving forward, by aiming to acquire official marketing approval for Collategene®, Mitsubishi
Tanabe Pharma and AnGes will continue working to provide a new treatment option for ulcers inpatients suffering from Peripheral artery disease that performance of revascularization is difficult.
We will also strive to promote appropriate use of Collategene® and help to increase the QOL ofpatients with critical limb ischemia.

About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma, which was founded in 1678, has its headquarters in Doshomachi,
Osaka, which is the birthplace of Japan’s pharmaceutical industry. With business centered on ethicalpharmaceuticals, Mitsubishi Tanabe Pharma is a well-established company and has the longest
history of any listed pharmaceutical company in Japan. In accordance with the corporate philosophyof “contributing to the healthier lives of people around the world through the creation ofpharmaceuticals,” the Company formulated the key concept of Open Up the Future under theMedium-Term Management Plan 16-20. Through the discovery of drugs that address unmet medical
needs, centered on its priority disease areas — immuno-inflammation, diabetes and kidney, central
nervous system, and vaccines — Mitsubishi Tanabe Pharma will strive to contribute to the health ofpatients around the world.
About AnGes
AnGes is a biopharmaceutical company focused on the development and commercialization ofgene-based medicines including gene therapy and oligonucleotide molecules. In addition to HGF
plasmid, which is the company’s lead product, AnGes is developing NF-kB Decoy oligonucleotide
for the treatment of inflammatory diseases. The company has facilities located in Tokyo and Osaka,
Japan and is listed on the Mothers Stock Exchange in Tokyo, a market for emerging companies.

Mitsubishi Tanabe Pharma
Media contacts: TEL: +81-6-6205-5119
Investor contacts: TEL: +81 6 6205 5110
https://www.mt-pharma.co.jp/e/
AnGes, Inc.
Corporate Communications
TEL: +81-3-5730-2641, FAX: +81-3-5730-2635

https://www.anges.co.jp/en/